Cost effectiveness of combination HIV therapy: 3 years later

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 325-330

  Moore, R D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0034107574     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00002     Document Type: Article

References (32)

1. 1. RD Moore JG Bartlett 1996 Combination antiretroviral therapy in HIV infection: an economic perspective Pharmacoeconomics 10 109 13 1:STN:280:DyaK28zjvFamtg%3D%3D 10163413 10.2165/00019053-199610020-00002 Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996; 10: 109-13
2. 2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: report of the NIH panel to define principles of therapy of HIV infection. MMWR Morb Mortal Wkly Rep 1998 Apr 24; 47 (RR-5): 1-41
3. 3. J Chancellor A Hill C Sabric 1997 Modeling the cost effectiveness of lamivudine/zidovudine combination in HIV infection Pharmacoeconomics 12 54 66 1:CAS:528:DyaK2sXltlWku74%3D 10169387 10.2165/00019053-199712010-00006 Chancellor J, Hill A, Sabir C, et al. Modeling the cost effectiveness of lamivudine/zidovudine combination in HIV infection. Pharmacoeconomics 1997; 12: 54-66
4. 4. J Mauskopf L Lacey A Kempel 1998 The cost effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates Am J Manage Care 4 1004 12 1:STN:280:DyaK1czotFKjuw%3D%3D Mauskopf J, Lacey L, Kempel A, et al. The cost effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manage Care 1998; 4: 1004-12
5. 5. L Lacey J Mauskopf R Lindrooth 1999 A prospective cotconsequence analysis of adding lamivudine to zidovudinecontaining antiretroviral treatment regimens for HIV infection in the U.S Pharmacoeconomics 15 23 37 10537440 10.2165/00019053-199915001-00003 Lacey L, Mauskopf J, Lindrooth R, et al. A prospective cotconsequence analysis of adding lamivudine to zidovudinecontaining antiretroviral treatment regimens for HIV infection in the U.S. Pharmacoeconomics 1999; 15: 23-37
6. 6. L Lacey M Youle P Trueman 1999 A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudinecontaining antiretroviral treatment regimens for HIV infection: European perspective Pharmacoeconomics 15 39 53 10537441 10.2165/00019053-199915001-00004 Lacey L, Youle M, Trueman P, et al. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudinecontaining antiretroviral treatment regimens for HIV infection: European perspective. Pharmacoeconomics 1999; 15: 39-53
7. 7. L Lacey PK Hopkinson J Montaner 1999 An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection: Canadian perspective Pharmacoeconomics 15 55 66 10537442 10.2165/00019053-199915001-00005 Lacey L, Hopkinson PK,Montaner J, et al. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection: Canadian perspective. Pharmacoeconomics 1999; 15: 55-66
8. 8. J Cook E Dasbach P Caplan 1999 Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial AIDS Res Hum Retrovir. 15 499 508 1:STN:280:DyaK1M3js1OitA%3D%3D 10221527 10.1089/088922299311024 Cook J, Dasbach E, Caplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retrovir. 1999; 15: 499-508
9. 9. Risebrough N, Oh P, Rachlis A, et al. Economic evaluation of triple ART with indinavir or abacavir and ZDV+3TC compared to dual therapy ZDV+3TC [abstract no. 103]. 6th Conference on Retroviruses and Opportunistic Infection; 1999 Jan 31–Feb 4; Chicago (IL)
10. 10. Freedberg KA, Goldie SJ, Paltriel AD, et al. Combination antiretroviral therapy is both effective and cost-effective [abstract no. 2070]. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
11. 11. FJ Hellinger 1993 The lifetime cost of treating a person with HIV JAMA 270 474 8 1:STN:280:DyaK3szgvVyjsA%3D%3D 8320787 10.1001/jama.1993.03510040078033 Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474-8
12. 12. CCJ Carpenter MA Fischl SM Hammer 1996 Antiretroviral therapy for HIV infection JAMA 276 146 54 1:STN:280:DyaK283nt12mtw%3D%3D 8656507 10.1001/jama.1996.03540020068031 Carpenter CCJ, Fischl MA, Hammer SM. Antiretroviral therapy for HIV infection. JAMA 1996; 276: 146-54
13. 13. K Simpson F Andersson A Shakespeare 1994 Cost effectiveness of antiretroviral treatment with zalcitabine in combination with zidovudine in AIDS patients with CD4 counts < 300 cells/mm 3 in five European countries Pharmacoeconomics 6 553 62 1:STN:280:DyaK28%2FlvVeqtA%3D%3D 10155284 10.2165/00019053-199406060-00008 Simpson K, Andersson F, Shakespeare A, et al. Cost effectiveness of antiretroviral treatment with zalcitabine in combination with zidovudine in AIDS patients with CD4 counts < 300 cells/mm 3 in five European countries. Pharmacoeconomics 1994; 6: 553-62
14. 14. RD Moore RE Chaisson 1997 Costs to Medicaid of advancing immunosuppression in an urban HIV infected patient population in Maryland J Acquir Immune Defic Syndr 14 223 31 1:STN:280:DyaK2s3jt1ekug%3D%3D 10.1097/00042560-199703010-00005 Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV infected patient population in Maryland. J Acquir Immune Defic Syndr 1997; 14: 223-31
15. 15. SF Hurley JM Kalder S Gardiner 1996 Lifetime cost of HIV related health care J Acquir Immune Defic Syndr 12 371 8 1:STN:280:DyaK28zgt1aksw%3D%3D 10.1097/00042560-199608010-00007 Hurley SF, Kalder JM, Gardiner S, et al. Lifetime cost of HIV related health care. J Acquir Immune Defic Syndr 1996; 12: 371-8
16. 16. S Petrou M Dooley L Whitaker 1996 The economic costs of caring for people with HIV infection in England and Wales Pharmacoeconomics 9 332 40 1:STN:280:DyaK28zitF2itw%3D%3D 10160107 10.2165/00019053-199609040-00006 Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection in England and Wales. Pharmacoeconomics 1996; 9: 332-40
17. 17. Ruane PJ, Ida J, Zakowski PC, et al. Impact of newer antiretroviral (ARV) therapies in inpatient and outpatient utilization of healthcare resources. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22-26; Washington, DC
18. 18. RA Torres M Barr 1997 Impact of combination therapy for HIV infection on inpatient census N Engl J Med 336 1531 2 1:STN:280:DyaK2s3ot1Ojsw%3D%3D 9157292 10.1056/NEJM199705223362118 Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1531-2
19. 19. P Kaiser MB Kvanli D Turner 1999 Protease inhibitor based therapy is associated with decreased HIV related health care costs J Acquir Immune Defic Syndr 20 28 33 10.1097/00042560-199901010-00004 Kaiser P, Kvanli MB, Turner D, et al. Protease inhibitor based therapy is associated with decreased HIV related health care costs. J Acquir Immune Defic Syndr 1999; 20: 28-33
20. 20. RD Moore K Gebo JG Bartlett 1999 Health care costs for 1995-1998 in AIDS AIDS 13 963 9 10371178 10.1097/00002030-199905280-00013 Moore RD, Gebo K, Bartlett JG, et al. Health care costs for 1995-1998 in AIDS. AIDS 1999; 13: 963-9
21. 21. Y Mouton S Alfandair M Valette 1997 Impact of protease inhibitors on AIDS-defining events and hospitalization in 10 French AIDS centers AIDS 11 101 5 10.1097/00002030-199712000-00003 Mouton Y, Alfandair S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalization in 10 French AIDS centers. AIDS 1997; 11: 101-5
22. 22. AH Anis RS Hogg X Wang 1998 Modeling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy Pharmacoeconomics 13 697 705 1:STN:280:DyaK1c3otVejtw%3D%3D 10179705 10.2165/00019053-199813060-00006 Anis AH, Hogg RS, Wang X, et al.Modeling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmacoeconomics 1998; 13: 697-705
23. 23. FJ Palella Jr KM Delaney AC Moorman 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 853 60 9516219 10.1056/NEJM199803263381301 Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
24. 24. A Morcroft S Vella TL Benfield 1998 Changing patterns of mortality across Europe in patients infected with HIV-1 Lancet 352 1725 30 10.1016/S0140-6736(98)03201-2 Morcroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30
25. 25. RS Hogg KV Heath B Yip 1998 Improved survival among HIV-infected individuals following initiation of antiretroviral therapy JAMA 279 450 4 1:STN:280:DyaK1c7is1Witg%3D%3D 9466638 10.1001/jama.279.6.450 Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4
26. 26. RD Moore RE Chaisson 1999 Natural history of HIV infection in the era of combination antiretroviral therapy AIDS 13 1933 42 1:STN:280:DyaK1MvktFyisw%3D%3D 10513653 10.1097/00002030-199910010-00017 Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933-42
27. 27. RM Gulick J Mellors D Havlir 1997 Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N Engl J Med 337 734 9 1:CAS:528:DyaK2sXmt1yit7s%3D 9287228 10.1056/NEJM199709113371102 Gulick RM, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
28. 28. SM Hammer KE Squires MA Fischl 1997 A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 337 725 33 1:CAS:528:DyaK2sXmt1yit7o%3D 9287227 10.1056/NEJM199709113371101 Hammer SM, Squires KE, Fischl MA, et al. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
29. 29. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine: three-year follow-up [abstract no. 388]. 6th Conference on Retroviruses and Opportunistic Infection; 1999 Jan 31-Feb 4; Chicago (IL)
30. 30. AW Wu RD Hays S Kelly 1997 Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS Qual Life Res 6 531 54 1:STN:280:DyaK2svntFKisA%3D%3D 9330553 10.1023/A:1018460132567 Wu AW, Hays RD, Kelly S, et al. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997; 6: 531-54
31. 31. RS Hogg AE Weber KJ Craib 1998 One world, one hope: the cost of providing antiretroviral therapy to all nations AIDS 12 2203 9 1:STN:280:DyaK1M%2FkvFKjug%3D%3D 9833862 10.1097/00002030-199816000-00016 Hogg RS, Weber AE, Craib KJ, et al. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS 1998; 12: 2203-9
32. 32. Forsythe S. The affordability of antiretroviral therapy in developing countries: what policymakers need to know [abstract no. 44245]. 12th International AIDS Conference; 1998 Jun 28-Jul 3; Geneva, Switzerland